Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) announced today that its shareholders have approved its combination with biotherapeutics firm Gelesis.
The deal was approved with a total of 24,835,281 votes in favor of the combination. A total of 25,643,831, or 74.3%, of CPSR’s issued and outstanding shares of common stock were present at yesterday’s special meeting. Although CPSR reached a high of $12.23 on January 10th, it quickly fell to a low of $6.06 today, and closed at $6.70.
The SPAC announced on Monday that all but $3.4 million have been removed from its trust via redemptions. A total of 27,260,179 shares were redeemed, including shares held by PIPE investors. Capstar noted that GCCU VI LLC and TOCU XXIX LLC redeemed 1,000,000 shares each, although each have also agreed to purchase 1,750,000 shares through the transaction’s PIPE. But, Capstar had already secured the deal’s completion in regards to its minimum cash condition by adding a backstop in late December.
Capstar also revised its agreement with Gelesis in early November in order to be re-struck on more investor-friendly terms. The changes slashed Gelesis’ proposed equity valuation by 25%, from $900 million to $675 million, in exchange for concessions on earnout shares and the sponsor’s promote.
The parties expect to close the deal shortly, and the combined company is expected to trade on the NYSE under the symbol “GLS”.
Capstar initially announced their combination on July 19. Boston-based Gelesis is advancing a series of therapies for weight management and chronic gut conditions with a consumer-facing approach.
ADVISORS
- Citi is serving as exclusive financial advisor to Gelesis
- Goodwin Procter LLP is serving as legal counsel to Gelesis.
- UBS Investment Bank is serving as exclusive financial and lead capital markets advisor to Capstar
- Kramer Levin Naftalis & Frankel LLP is serving as Capstar’s legal counsel.
- UBS Investment Bank and Citi are serving as private placement agents to Capstar with respect to the PIPE financing.
- Winston & Strawn LLP served as counsel to the placement agents.
- BTIG, LLC is also serving as a capital markets advisor to Capstar.
Remember the metaverse? Many do not. Meta’s (NASDAQ:META) attempted transition to virtually living and working seemed to mark a trend that went up and down quickly, but one SPAC deal has both survived that roller coaster and may rise with a second. Back in December 2022, Newbury Street (NASDAQ:NBST) announced a $1.85 billion combination with...
At the SPAC of Dawn Tucked into the bill that provides $95 billion in funding to American allies passed by the House this weekend is another measure that is likely to have far more impact on at least one pending deal in SPAC world. It would appear that the timing was fortuitous for TikTok rival...
With the passage this weekend of $95 billion in funding for Ukraine, Israel and Taiwan by the House of Representatives, some focus has gone back towards the defense sector, which has generally had a good year as a whole. But, SPACs have not been as active in defense, despite the fact that companies in the...
At the SPAC of Dawn As April’s sleepy month for SPAC news continues, there is only one special meeting on the docket to consider a SPAC deal approval, that being today’s vote on Pegasus Digital Mobility‘s (NYSE:PGSS) combination with equipment manufacturer Schmid. Three more SPACs are facing extension votes this week, including Pyrophyte (NYSE:PHYT), whose...
Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...